Company intelligence / Profile preview

Ellipses Pharma

London, England, United Kingdomellipses.life ↗

Ownership: Private
Development stage: Phase 2

Overview

Preliminary results from ongoing Phase 1/2 studies of EP0042 show favorable safety and initial efficacy in AML. EP0057 has orphan drug designation and is being evaluated in phase 2 studies for advanced ovarian cancer with olaparib. The company recently announced the development of a next-generation immuno-oncology checkpoint inhibitor.

Therapeutic areas: Oncology
Modalities: Small molecules (e.g., kinase inhibitors)Nanoparticle drug conjugatesImmuno-oncology agents (checkpoint inhibitors)
Industry: Biotech

Drug pipeline

7 assets

vosilasarm

6 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with global key opinion leaders via its Scientific Affairs Group to guide asset selection and trial design.

Beyond the preview

Go deeper on Ellipses Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ellipses Pharma.

Explore the full profile